Goldman Sachs analyst Davin Thillainathan initiated coverage of CSL (CSLLY) with a Buy rating and A$325.40 price target The firm believes the company’s investments in its immunoglobulin franchise and new product launches in the Behring portfolio are set to increase return on invested capital.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSLLY: